Review

Regulation of CD4+ and CD8+ T Cell Biology by Short-Chain Fatty Acids and Its Relevance for Autoimmune Pathology

Carmen Schiweck 1,* 1, Sharmili Edwin Thanarajah 1, Mareike Aichholzer 1, Silke Matura 1, Andreas Reif 1, Elske Vrieze 2, Andreas Weigert 3 and Alexander Visekruna 4

1 Department for Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt-Goethe University, 60528 Frankfurt, Germany; sharmili.edwinthanrajah@kgu.de (S.E.T.); mareike.aichholzer@kgu.de (M.A.); silke.matura@kgu.de (S.M.); andreas.reif@kgu.de (A.R.)
2 Department of Psychiatry and Neurosciences, UPC KU Leuven, Campus Gasthuisberg, KU Leuven, 3000 Leuven, Belgium; elske.vrieze@uzleuven.be
3 Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt/Main, 60590 Frankfurt, Germany; weigert@biochem.uni-frankfurt.de
4 Institute for Medical Microbiology and Hygiene, Philipps-University Marburg, 35043 Marburg, Germany; visekrun@staff.uni-marburg.de
* Correspondence: carmen.schiweck@kgu.de

Abstract: The gut microbiota encodes a broad range of enzymes capable of synthesizing various metabolites, some of which are still uncharacterized. One well-known class of microbiota-derived metabolites are the short-chain fatty acids (SCFAs) such as acetate, propionate, butyrate and valerate. SCFAs have long been considered a mere waste product of bacterial metabolism. Novel results have challenged this long-held dogma, revealing a central role for microbe-derived SCFAs in gut microbiota-host interaction. SCFAs are bacterial signaling molecules that act directly on host T lymphocytes by reprogramming their metabolic activity and epigenetic status. They have an essential biological role in promoting differentiation of (intestinal) regulatory T cells and in production of the anti-inflammatory cytokine interleukin-10 (IL-10). These small molecules can also reach the circulation and modulate immune cell function in remote tissues. In experimental models of autoimmune and inflammatory diseases, such as inflammatory bowel disease, multiple sclerosis or diabetes, a strong therapeutic potential of SCFAs through the modulation of effector T cell function was observed. In this review, we discuss current research activities toward understanding a relevance of microbial SCFA for treating autoimmune and inflammatory pathologies from in vitro to human studies.

Keywords: short chain fatty acid; immune system; T cell; intervention; RCT

1. Introduction

Aberrant immune responses are the core mechanism behind several autoimmune pathologies such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and diabetes. Regulating the delicate balance of inflammatory mediators is key for treatment of these pathologies. Next to monoclonal antibodies, non-steroidal and steroidal anti-inflammatory drugs, in recent years, the gut microbiota has received much attention as treatment target for autoimmune pathologies [1]. Increasing awareness of the bidirectional role the gut microbiota plays in the communication with both the brain and periphery has prompted several studies investigating various treatment options to modify the gut microbiome and thus tamper inflammation. These studies include dietary interventions including pre-, pro- and synbiotics, as well as fecal microbial transplants (e.g., clinical trial registration numbers: NCT03766321, NCT04038619, NCT03766321, NCT04574024). One converging agent that may be behind the mechanism for this modulation by the above-mentioned treatments, are short-chain fatty acids (SCFAs). SCFAs are implicated in immune cell metabolism and regulation and can have both beneficial and deleterious
consequences for inflammation, depending on the type, site of action, milieu, dose, target cell type and duration of exposure. While it is understood that SCFAs modulate the immune system through their action on epithelial cells [2,3] the past decade has also revealed a stimulating effect on B cells [4], Immunoglobulin A (IgA) responses [5] and diverse T cell subsets [6,7]. Modulation of pathogenic T cell activity is a major focus of interest for treatment of autoimmune disorders and several intervention studies have been published in the past 3 years. To our knowledge, no review summarizes the current literature on the effect of SCFA interventions on CD4\(^+\) and CD8\(^+\) T cell responses in animal and human studies of the above-mentioned autoimmune disorders. Therefore, we here examine the recent literature on butyrate, acetate, propionate and valerate and their impact on T helper and cytotoxic T cell biology.

What Are Short-Chain Fatty Acids?

Saturated fatty acids with a maximum of 5 carbon atoms are called SCFAs and are defined by the number of carbon atoms present. Among the SCFAs, formate (C1), acetate (C2), propionate (C3), butyrate (C4), and valerate (C5) take the center stage in the scientific literature. In humans, acetate, butyrate and propionate are found in higher concentrations than valerate or formate [8]. SCFAs are produced through fermentation of undigested carbohydrates by anaerobic bacteria in the colon [9]. In the case of acetate, it can also be derived from hydrogen and carbon dioxide or formic acid by acetogenic bacteria [10]. Since microbes provide the essential enzymes for SCFA production [11], a healthy gut microbiome is essential for immune homeostasis. SCFAs are used as energy source for colonocytes [12] and the microbiota [13], but can also have potent immunological properties. For instance, SCFAs can influence (i.e., both induce and reduce) the production of cytokines by epithelial cells [14,15]. Recently, it was reported that SCFAs can also influence T cell responses [7].

Most SCFAs are absorbed in the gut and only a small portion (estimated at around 5%) is excreted [16]. SCFAs thus may likely have the strongest influence on (T) cells locally in the colon, where concentrations can reach up to ~130 mmol/kg in the caecum [8]. However, SCFAs also enter the circulation via the blood stream in lower, though still detectable concentrations. Particularly acetate, and to a lesser extent propionate and butyrate, are found in the blood stream of healthy people (from around 20–500 \(\mu\)mol/L for acetate, 1–13 \(\mu\)mol/L for propionate and 1–12 \(\mu\)mol/L for butyrate) [8,9,17,18] and may thus also exert systemic effects (see Table 1). Given that the site of action (e.g., local versus systemic) differs considerably in terms of exposure, cell types involved and the milieu, in the following we point out where and under which circumstances the different effects occur.

Table 1. Physiological concentration of SCFAs in the healthy human colon and blood (fasted), as reported in the literature. Note that higher concentrations may be found in arterial blood compared to venous blood [19].

| SCFA   | Colon (Caecum) | Blood (Serum/Plasma, Fasted) | References |
|--------|---------------|-------------------------------|------------|
| Total SCFA | 131 mmol/kg | ~79–510 \(\mu\)mol/L | [8,17] |
| Acetate | 44–69 mmol/kg | ~5–402 \(\mu\)mol/L | [8,9,17] |
| Propionate | 14–25 mmol/kg | 3.3–ca.15 \(\mu\)mol/L | [9,17,18] |
| Butyrate | 15–26 mmol/kg | 2.1–10 \(\mu\)mol/L | [9,18] |
| Valerate | ~4.5 mmol/kg | 1.3–ca 4 \(\mu\)mol/L | [8,17,18] |

2. Effect of SCFAs on General Function of T Cells in the Gut and Periphery

Two major subclasses of T cells are T helper and cytotoxic T cells. T helper cells are defined by the expression of the cluster of differentiation (CD) 4 that, together with the specific T cell receptor, allows the recognition of peptides presented on the Major
histocompatibility complex (MHC) class II e.g., [20]. Cytotoxic T cells express CD8 next to the T cell receptor, recognize peptides on MHC class I and are particularly important for intracellular pathogen recognition. CD4+ T cells are involved in shaping adaptive immune responses and have highly specialized functions with a primary function in extracellular antigen recognition. Upon activation, Th cells differentiate into discrete, but partly interconvertible subsets with specific functions, such as Th1, Th2, Th17 and regulatory T cells (Treg). Two types of T helper cells play a particular role in the delicate balance of homeostasis and prevention of inflammation, particularly in the gut: T regulatory and interleukin (IL)-17 producing T cells. Given the scope of this review, we here focus majorly on CD8+ cells, Tregs and two subsets of IL-17 producing cells: T helper (Th) 17 and γδ T cells.

2.1. Effect on Tregs

Current evidence indicates that SCFAs can have an anti-inflammatory effect which can be exerted via different mechanisms (for a review see [2]). Next to strong effects on epithelial and dendritic cells, macrophages and neutrophils, SCFAs have a strong IgA inducing effect [4,5] and promote Treg differentiation and responses [6,7,21,22].

Forkhead box P3 (Foxp3) positive regulatory T cells recognizing commensal epitopes (cTregs) maintain homeostasis by promoting tolerance through IL-10 production, prevention of intestinal inflammation [23] and tissue repair [24]. In contrast, Th17 cells can mediate both regulatory and inflammatory functions [25] and can secrete high amounts of IL-17. Th17 cells are considered to have a classical T cell receptor, as most T cells, which is composed of an α and β chain, whereas the T cell receptor of γδ T cells is composed of a γ and δ chain. γδ T cells are unconventional T cells, since unlike the classically adaptive αβ T cells, they unite adaptive and innate immune characteristics [26]. Their innate function is exemplified by their ability to be activated independent of their T cell receptor recognizing the MHC–antigen complex. Instead, they respond very rapidly to innate stimuli such as cytokines, secreting in turn various cytokines themselves, including IL-17. The large majority of γδ T cells is tissue resident [27]. This T cell type is particularly high in the gut [28] and may thus play an important role regarding the immune balance where IL-17 is involved.

A disturbed balance between regulatory and IL-17 producing cell types, which are highly concentrated in the lamina propria, is thought to play a crucial role in autoimmune pathology and intestinal inflammation [29]. It is understood that specific strains of commensal bacteria can induce Treg and/or Th17 cell expansion and differentiation (e.g., [30–32], but whether this is due to a direct response to specific bacteria or rather to their by-products was incompletely understood until the early 2000s. In 2013, Furusawa showed that differentiation of Tregs can be directly induced by the SCFA butyrate, both in vivo and in vitro, even under Th1 or Th17 polarizing conditions. The luminal concentration of butyrate also correlated with the number of Tregs [22]. Adding to this, Arpaia et al. (2013) further found that this increased differentiation of Tregs after butyrate exposure was due to peripheral induction, and not increased thymic output [21]. Interestingly, the increased differentiation of Tregs could be observed for butyrate and in the periphery also for propionate, but not for acetate [21,22]. Around the same time, Smith et al. showed that SCFAs which were orally administered to germ-free mice for 3 weeks, increased the number of cTregs. However, this effect was not observed in Treg populations found in the mesenteric lymph nodes, spleen or thymus [6]. These findings show that the specific local effects of SCFAs on Treg differentiation and colonization do not necessarily extend to the periphery, be that due to exposure to different doses, higher expression and thus regulation of GPR43 in colonic Tregs [6] or other mechanisms (see Figure 1).
The epithelial barrier function that are capable of crossing the epithelial barrier and of acting directly on immune cells in the lamina propria. SCFAs promote the epithelial barrier function, local expansion of colonic Tregs and mucosal IgA responses. Microbiota-derived molecules such as SCFAs are also able to reach the circulation and to influence the host health by strengthening anti-viral and anti-cancer T cell responses as well as suppressing autoimmunity and inflammation in peripheral tissues.

2.2. Effect on Effector Th17 Cells

Often considered as counterbalance of T regulatory cells, IL-17-producing Th17 cells can induce tissue inflammation in auto-immune responses, but they are also crucial for combating pathogen infection and exert protective effects [33,34]. These functions partly depend on the different cytokines produced by Th17 cells: IL-21 promotes IgA production, while IL-22 is thought to induce tissue repair and increase the epithelial barrier function [34]. Regarding the modulation by SCFAs, Park and colleagues (2015) observed an acetate- and propionate-induced, dose-dependent increase in Th17 and Th1 cells depending on the cytokine milieu. This was also observed in the spleen and mesenteric lymph nodes [7]. This finding is important since it suggests that the observed effect is not locally restrained. Increased Th1 and Th17 cells are often linked to increased auto-immune pathology and would thus be detrimental for disease progression. However, when acetate-treated cells were transferred to induce colitis in mice, the Th17 cells only induced mild inflammation and were not as pathogenic as control effector T cells [7]. This was also observed by others and is likely linked to the simultaneous high production of IL-10 by these Th17 cells [35]. Most importantly, the clinical relevance of this finding becomes clearer when considering human studies. Production of IL-17 by human Th17 cell derived from patients with multiple sclerosis, or by γδ T cells from patients with inflammatory bowel disease (IBD) can be strongly suppressed by supplementation of SCFAs such as propionate (see below for a more detailed overview) [36,37].

2.3. Effect on CD8+ Cells

SCFAs can also exert a potent antiviral function and can regulate autoimmunity and inflammation, partly via the regulation of cytotoxic CD8+ cell subsets (see Figure 1). For instance, Trompette et al. (2018) showed that oral administration of SCFAs conferred protection to influenza infection (i.e., improved clinical scores and enhanced survival rates) by reducing neutrophil infiltration, reducing tissue damage and increasing CD8+ T cell activation [38]. Interestingly, Bachem et al., also found that butyrate potentiates metabolism and improves anti-viral immunity of CD8+ T cells in the spleen and liver.

Figure 1. Bacterial fermentation of dietary fiber in the intestinal lumen leads to generation of SCFAs such as acetate, propionate, butyrate and pentanoate. Microbial SCFAs are potent signaling molecules that are capable of crossing the epithelial barrier and of acting directly on immune cells in the lamina propria. SCFAs promote the epithelial barrier function, local expansion of colonic Tregs and mucosal IgA responses. Microbiota-derived molecules such as SCFAs are also able to reach the circulation and to influence the host health by strengthening anti-viral and anti-cancer T cell responses as well as suppressing autoimmunity and inflammation in peripheral tissues.
This process was suggested to happen by boosting CD8\(^+\) memory T cell survival and activation through increased glycolysis and increased acetylation of glyceraldehyde-3-phosphate dehydrogenase [39]. Next to their anti-viral properties SCFAs can also exert anti-tumor effects [40,41]. Since SCFAs serve as important metabolic energy source for cells, and given the fact that in the tumor microenvironment T cells compete for glucose with cancer cells, Qiu and colleagues explored whether in vitro, acetate could restore CD8\(^+\) responses [42]. The authors showed that acetate was able to rescue hypo responsive CD8\(^+\) T cell functions by increasing cytokine production and histone acetylation but did not affect lactate production or cell proliferation.

The reinforcing effect of SCFAs on CD8\(^+\) T cell responses is not limited to acetate. He et al. (2021) have shown that butyrate increases CD8\(^+\) T cell antitumor responses in the tumor microenvironment [43]. Luu and colleagues demonstrated that both butyrate and pentanoate improved immunotherapy for cancer by boosting CD8\(^+\) T cell and chimeric antigen receptor (CAR) T cell responses [44]. Interestingly, butyrate concentrations also correlated with clinical outcomes. Responders to oxaliplatin, which is used for treatment of colorectal cancer, had higher levels of butyrate than non-responders [43]. It is now clear that the microbiome is crucially involved in the efficacy of anti-tumor immune therapies [45], a process in which SCFAs may play a decisive role. However, randomized clinical trials are needed to make definite statements as to the efficacy of SCFAs alone or in combination with established therapies in patients with cancer.

2.4. Anti-Inflammatory Effect in Periphery Is Dose-Dependent

As shown in the Figure 1, current evidence suggests that SCFAs generally induce an anti-inflammatory effect in the gut, and potentially in the periphery. Several of the above-mentioned studies found different effects based on the dose of SCFAs.

Delivering SCFAs in mouse models is usually performed by administration in the drinking water, oral gavage, or intraperitoneal injection. Since SCFAs can be derived from naturally occurring fibre, dietary interventions including fibre, pre- and probiotics are a convenient means to increase peripheral SCFA concentrations in humans. Other options to deliver SCFAs include enemas, capsules or even delivering microbial strains that are thought to produce SCFAs. Blaak et al. (2020) recently reviewed the literature regarding in vivo studies assessing the concentrations that can be found in the colon and periphery and as others (e.g., Cummings et al., 1987), have reported much lower concentrations in the periphery than in the colon [8,9].

The concentration of most SCFAs in the peripheral bloodstream is approximately between 1–15 \(\mu\)mol/L [8,9,18] at the exception of acetate, which can reach concentrations up to 500 \(\mu\)mol/L [17] (see Table 1). However, concentrations in the colon and those used for in vitro studies are often around 100 \(\mu\)M or higher (e.g., [6,21]. Importantly, the effect of SCFAs on Th1/Th17 cells described by Park and colleagues occurred only at relatively high concentrations (e.g., 5 mM for acetate and 0.5 for propionate, see below), but not at levels below this threshold [7]. It therefore stands to question whether the same effects seen in vitro can be induced in vivo in animals or humans, using interventional strategies. Qi Hui et al. (2021), investigated the effect of 2 \(\mu\)mol, 20 \(\mu\)mol and 200 \(\mu\)mol butyrate on cytokine production in human peripheral blood mononuclear cells (PBMCs) stimulated with lipopolysaccharide [46]. Levels of IL-6 and IL-1\(\beta\) were significantly reduced at concentrations of 20 \(\mu\)mol, whereas concentrations of 2 \(\mu\)mol did not show any effect. Similar effects were observed for propionate, for IL-18 and TNF-\(\alpha\), but no effect was observed for acetate. Coutzac et al. (2020) reported that the increase of Tregs after CD3 stimulation in vitro was found with butyrate concentrations of 50 \(\mu\)M or 100 \(\mu\)M, but not at concentrations of 10 \(\mu\)M [47]. This may suggest that physiological concentrations can potentially be sufficient to induce an anti-inflammatory effect, but especially for butyrate and propionate the concentrations would be below the window of efficacy. It should however also be noted that most studies reported no effect for acetate when butyrate or propionate were effective. See Table 2 for an overview of concentrations used in different studies.
Table 2. Concentrations used in pivotal studies with in-vitro experiments with Treg/Th17 cells in humans and mice.

| Author | Experiment | Cells Used for Assay | SCFA Used | Dose Used | Effect For | No Effect For | Outcome |
|--------|------------|----------------------|-----------|-----------|------------|--------------|---------|
| [48]   | Lymphocyte proliferation assay, cytokine production | rat lymphocytes (from lymphnodes) | acetate, butyrate, propionate | acetate 10 mM, butyrate 1.5 mM, propionate 2 mM | Butyrate at 0.25 mM–1.5 mM | acetate, propionate (IL-2) | ↓ Thymidine incorporation ↑ IL-10 production after 48 h for acetate, propionate or a combination of both/with butyrate; ↓ IL-10 after 24 h for butyrate alone buyrate inhibited IL-2/IFN-γ production |
| [22]   | Induction of Treg cells in vitro | splenic naïve (CD44<sup>lo</sup> CD62L<sup>hi</sup>) CD4+ T cells | (Sodium) acetate, butyrate propionate | 0.1 mM | Butyrate, propionate | acetate | ↑ Tregs for butyrate, moderately for propionate, no effect for acetate |
| [21]   | Induction of extrathymic Tregs in vitro | Peripheral naïve (CD44<sup>lo</sup> CD62L<sup>hi</sup>CD25<sup>−</sup>) CD4+ T cells | Butyrate, isovalerate, acetate, propionate | 0–1024 µM | Butyrate, isovalerate, propionate | acetate | ↑ FOXP3+ cells |
| [6]    | Purified cTregs from GF mice cultured for 24 h | cTregs from GF mice | propionate | 0.1 mM | propionate | – | ↑ IL-10 expression; ↑ IL-10 protein; ↑ FOXP3 expression, no effect for TGF-β |
| [7]    | Effect of SCFAs under; anti-CD3/CD28 in a Th17 or Th1 condition | naive CD4<sup>+</sup> T cells | acetate, propionate, butyrate | acetate: 0–20 mM propionate: 0–1 mM | Optimal: acetate 5–20 mM; propionate: 0.5–1 mM | acetate (<1 mM), propionate (<0.5 mM) | ↓ Th1 and Th17 differentiation ↑ expression of IL-17A, IL-17F, RORα, RORγt, T-bet, and IFN-γ ↑ FOXP3 in low anti-CD3 (1 µg mL<sup>−1</sup>) activation condition ↑ high IL-10 expression ↑ IL-10, IFN-γ, and IL-17 in CD8<sup>+</sup> T cells |
| [49]   | peripheral blood mononuclear cells (PBMCs)/ | Human PBMCS | butyrate, propionate, acetate | Propionate+acetate: 0–6.4 mM; butyrate: 0–1.6 mM | butyrate, propionate | acetate | ↓ expression of CD25 in CD4<sup>+</sup> and CD8<sup>+</sup> cells, butyrate (0.1–0.4 mM) ↑ CTLA-4 |
| [50]   | Treg & Th17 polarizing conditions | human naive CD4<sup>+</sup> T cells (CD45RA<sup>−</sup> CD45RO<sup>+</sup> CD25<sup>−</sup> CD127<sup>+</sup>) | propionate | 1 µM–10 mM (Treg), 150 µM Th17 | 10mM propionate | ↑ CD4<sup>+</sup>CD25<sup>+</sup>Fox3<sup>+</sup> cells; ↑ proliferation of differentiated Tregs; ↑ CD4<sup>+</sup>IL-17A<sup>+</sup> T cells |
| [47]   | CD3 stimulation | Human PBMCS | butyrate | 0–100 µM, 50 µM and 100 µM | 10 µM butyrate | ↑ % of Tregs in PBMCs | <0.25 mM: ↑ FOXP3 and inducible Treg differentiation only when TGF-β was suboptimal; absence or presence of high TGF-β abolished effects of butyrate; >0.25 mM: abolished effect of Treg differentiation, induction of IFN-γ (not IL-17A or IL-4) |
| [51]   | CD3 stimulation/Treg polarizing conditions | Murine CD4<sup>+</sup> cells from lymph nodes/spleen | butyrate, propionate, acetate | 0.1–10 mM | Increased regulatory expression: 0.1–0.25 mM; suppress regulation: 0.5 mM–1 mM | acetate, butyrate >0.5 mM induced IFN-γ but not Tregs | 10 µM butyrate | ＜0.25 mM: ↑ FOXP3 and inducible Treg differentiation only when TGF-β was suboptimal; absence or presence of high TGF-β abolished effects of butyrate; >0.25 mM: abolished effect of Treg differentiation, induction of IFN-γ (not IL-17A or IL-4) |

Abbreviations: IL: interleukin; FOXP3: forkhead box P3, ROR: retinoic acid–related orphan nuclear receptor, IFN: Interferon, TGF: transforming growth factor.
A second question is what concentrations of SCFAs can be reached in the peripheral blood after oral ingestion, which is arguably the preferred intervention method in humans. A study in healthy controls ingesting daily concentrations of oral capsules with high-dose, colon-delivered acetate (174.2 mmol), propionate (13.3 mmol) and butyrate (52.4 mmol) found that serum concentrations of acetate, butyrate and propionate nearly doubled after a 1-week intervention, reaching concentrations of 84.08 µM, 1.40 µM and 2.04 µM respectively [52]. Although increased, the level in sera after such an intervention may still be too low to reach efficacy in peripheral blood. This does naturally not mean that SCFAs cannot have a significant impact in the colon, however in humans, as biopsies are rare, this is more difficult to assess.

3. SCFA Interventions in Inflammatory Disorders

Given the potent immune-modulatory functions demonstrated above, the question arises whether SCFAs may be instrumental in modulating unwanted or exaggerated immune responses, as seen in autoimmune pathologies. In the following we will examine animal and human studies which assessed CD4+ and CD8+ T cell function upon SCFA exposure with an emphasis on autoimmune pathologies.

3.1. Multiple Sclerosis

Several studies have investigated the association of serum SCFA concentrations, inflammatory proteins and circulating T cell subsets in humans with and without disease. Some evidence for the beneficial effect of SCFAs supplementation exists for multiple sclerosis (MS). MS is a central nervous system (CNS) autoimmune disease with a role for autoreactive B and T cells: T cell subsets implicated in MS are particularly cytotoxic CD8+ cells, Th1 and Th17 cells [53]. The association between levels of SCFAs and MS has been shown in several association studies. Low levels of serum/plasma propionate, acetate and butyrate were found in patients with clinically isolated syndrome or MS compared to controls [54,55]. However, others reported contradictory findings or no changes for acetate, propionate, butyrate or valerate in blood or stool samples [17,56]. Only few studies have investigated the number of circulating cells in relation to SCFAs. In a small sample no association was found between levels of acetate, butyrate or propionate with circulating Treg, Th1 or Th17 cells, but a small positive association of T follicular cells with serum butyrate and propionate levels was detected [55]. Pérez-Pérez and colleagues showed higher levels of acetate in blood of MS patients, which correlated with IL-17 producing CD8+ T cells [57]. Lastly, Zeng et al. (2019) detected a positive association between fecal concentrations of SCFAs and numbers of peripheral Tregs [58]. For an overview of association studies see Table 3.

Table 3. Association studies of SCFA and in humans with autoimmune pathology.

| Reference | Groups | SCFA Studied | SCFA Measured In | Concentration in Patient Group | Findings |
|-----------|--------|--------------|-----------------|-------------------------------|----------|
| [55]      | 30 MS/CIS 10 HC acetate, butyrate, propionate blood concentrations in nmol/mL: acetate: ~1600; butyrate: ~14; propionate: ~160 | lower propionate in MS than controls butyrate positively correlates with Tfh cells no association of SCFAs with Treg, Th1 or Th17 counts |
| [17]      | 58 (RR)MS 50 HC acetate, propionate, butyrate, valerate blood concentrations in µmol/L: total SCFA 453; acetate 349; butyrate: ~6.4; propionate ~15 valerate: ~3.8 | lower total SCFAs concentration in MS compared to controls no individual difference for acetate butyrate, propionate or valerate between MS and controls after multiple testing correction no significant correlation of SCFAs with inflammatory cytokines in patients with MS positive association of butyrate with TNF and IFN-γ in HC, negative correlation of acetate and IFN-γ SCFA levels not related to clinical follow up at 12 months |
Table 3. Cont.

| Reference | Groups | SCFA Studied | SCFA Measured In | Concentration in Patient Group | Findings |
|-----------|--------|--------------|------------------|---------------------------------|----------|
| [57]      | 95 MS  
54 HC | acetate | blood | approximate mean values in µM/L: acetate: ~25; propionate: ~3.9; butyrate: ~3.8 | higher acetate levels in blood of patients with MS; positive association with CD4+IL-17+ (not significant after correction) and CD8+IL-17+ cells, negative association with naive CD4+ cells |
| [58]      | 34 MS/ 
12 MS for 
cells  
34 HC | propionate, butyrate, acetate | fecal samples | na | depletion of fecal acetate, propionate, and butyrate in MS; fecal SCFA level positively correlated with pTreg frequency |
| [56]      | 41 MS/35 
controls | propionate, butyrate, acetate | fecal samples | median concentrations in mmol/g: acetate 41.70; propionate 5.51/butyrate 1.25/valerate | non-significantly lower SCFA concentrations in MS compared to controls |

Type 1 Diabetes

| Reference | Groups | SCFA Studied | SCFA Measured In | Concentration in Patient Group | Findings |
|-----------|--------|--------------|------------------|---------------------------------|----------|
| [59]      | 19 patients with T1D and matched controls+animal model | acetate, butyrate | feces | total µg/g: acetate ~1700; butyrate ~1600 | significantly lower SCFA concentrations (butyrate, propionate acetate) in T1D; valerate levels similar |

Rheumatoid arthritis

| Reference | Groups | SCFA Studied | SCFA Measured In | Concentration in Patient Group | Findings |
|-----------|--------|--------------|------------------|---------------------------------|----------|
| [61]      | 82 people with increased risk for RA | acetate, butyrate, propionate or pentanoate | blood | serum in um: acetate: ~80; butyrate: ~3; pentanoate: ~4.5; Propionate ~8 | higher total sum of SCFAs and/or butyrate/acetate in people who did not develop RA; butyrate correlated negatively with serum IgA-anti-citrullinated protein antibody levels but not with IgG or IgM isotypes; T cells were not assessed |
| [62]      | 19 RA, 
20 HC 
stool/13 HC 
14RA blood | acetate, butyrate, propionate | stool and blood | concentrations in stool, µmol/g: acetate: ~7; propionate ~2, butyrate ~1.8; in blood µmol/g: acetate: ~30, propionate ~2, butyrate ~10 | stool: significant reduction in butyrate/propionate, no difference in acetate; serum: no difference in propionate/butyrate but significant increase in acetate; butyrate correlates positively with circulating IL-10+ B cells in serum. |
| [63]      | 9HC  
10RA | acetate, butyrate, propionate, valerate | stool | concentrations in umol/g: acetate ~9, propionate ~1.5, butyrate ~5; valproate ~0.19 | lower acetate, propionate, butyrate and valerate in patients compared to controls |
| [64,65]   | 10 HC 
36/29 RA | acetate, butyrate, propionate | stool and serum | in mM: in serum: total in mM: ~0.2; acetate: ~0.2; propionate: ~0.015, butyrate ~0.004 | no comparison between HC and RA patients regarding SCFAs; inflammatory cytokines were not higher at baseline, but patients received DMARD therapy |

Abbreviations: Tfh: follicular T helper cells; Th: T helper cell; MS: Multiple sclerosis; RA: rheumatoid arthritis; T1D: Type 1 diabetes; IBD: Inflammatory bowel disease; HC: healthy control; CIS: clinically isolated syndrome; Ig: Immunoglobulin; na: not applicable.

Next to these association studies, attempts have been made to address the modulating effect of SCFAs on T cell subsets, both in autoimmune models in animals and autoimmune pathology in humans. Fatty acids have long been known to modulate disease activity in MS: While long chain fatty acids are thought to exacerbate autoimmune activity by favoring differentiation of Th1 and Th17 cells [50], SCFAs may have a beneficial effect. Haghiakia and colleagues (2015) found that propionate not only increased the frequency of Tregs derived from naïve T cells, but also changed the proliferation of previously differentiated Tregs and increased IL-10 (but not IL-17) production [50]. Haase et al. (2021) recently showed that this beneficial effect of propionate may be particularly useful in case of a high-fat diet. In their experimental autoimmune encephalitis (EAE) mouse model, high fat diet
aggravated the disease progression, but propionate prevented this effect [66]. The authors found that in this context, propionate particularly reduced Th17 cell-related inflammation and increased Treg function and numbers [66]. Importantly, the authors were able to show that in a small trial, a 90-day treatment of propionate also increased Treg counts (in non-obese MS patients) and reduced Th17 cell count (in the obese patient population). One of the few other studies in humans with MS, which focuses on a specific SCFA, showed that in patients with MS, short-term oral administration of propionate for 14 days led to a significant reduction in Th17 cells and an increase in Treg counts. Long term treatment (e.g., follow-up between 1-3 years) improved clinical outcome as measured by disability status and relapse rates [37]. Importantly, Haghikia et al. (2015) also demonstrated that the timing of SCFA administration is crucial, since SCFAs had a preventive effect if given at the time point of immunization in their EAE mouse model but had no effect at the time of disease onset, suggesting that preventive administration may be the key and indicating that SCFAs may generate tolerance towards the model antigen [50]. However, these results await confirmation human studies with larger patient collectives. In a nutshell, the first evidence summarized here suggests that propionate may have the potential to reduce Th17 numbers and increase Treg frequency and functionality. If this is due to regulating IL-10 secretion or other mechanisms of immune tolerance remains to be determined. Further controlled intervention studies in humans are needed.

3.2. Type I Diabetes

One of the autoimmune disorders with the strongest evidence for a pathogenic role of T cells is Type 1 diabetes (T1D). In contrast to Type 2 diabetes, where peripheral cells become resistant to insulin over time [67], in T1D, pancreatic insulin-producing beta cells are destroyed by autoreactive T cells early on, with a particular pathogenic role of CD4+ and CD8+ cells [68]. First evidence for decreased SCFA concentrations also exists for T1D [59,60], although further studies are needed to replicate this effect. Strong evidence for a positive effect of a SCFA intervention on T1D comes from first animal and human studies: In 2017, Mariño et al. (2017) made several ground-breaking observations: In a non-obese diabetic (NOD) mouse model of type I diabetes, a 5-week special diet designed to release high amounts of either acetate or butyrate led to higher levels of SCFAs in feces and blood [69]. Interestingly, combining both diets prevented the development of T1D in the NOD mouse, likely involving different cellular mechanisms. However, this was only true at relatively high ingested concentrations (i.e., 15%), but not at a lower dose (e.g., 7.5%) [69]. Interestingly, the acetate-rich (and, to a lower extent, the butyrate-rich) diet reduced the frequency of autoreactive CD4+ and CD8+ T cells, and led to expansion of CD4+Foxp3+ Treg cells both in the colon and spleen, but not in peripheral lymph nodes [69]. The diets were also able to indirectly reduce autoreactive T cells. Upon adoptive transfer of T cells from mice fed either with a control diet, acetate-rich diet or butyrate-rich diet, into mice with severe combined immunodeficiency, it was particularly the butyrate rich-, but not the acetate-rich diet which delayed diabetes onset [69]. The butyrate rich diet conferred its protective effect in the adoptive transfer model to the immune-deficient mice by enhanced Treg function and differentiation of Tregs from naïve T cells. The authors emphasized that since acetate seemed to primarily reduce effector T cells and butyrate increased regulatory subsets. The combination of both thus may yield the strongest effect.

Recently, Bell et al. (2022) partly confirmed these results in humans with T1D: Using a 6-week intervention with a dietary combined butyrate and acetate enhancing supplement comparable to the animal study by Mariño et al. (2017). They demonstrated an increase of fecal and peripheral SCFA concentrations after treatment [70]. While the change of T and B cell subsets was not identical to the data of Mariño et al., they did observe a shift in B cells after 6 weeks of treatment and a delayed effect for B and T cells, 6 weeks after completion of the treatment (follow-up). At 6 weeks, total (naïve) B cells were increased, alongside decreased expression of the costimulatory molecule CD86. At 12 weeks, T-cell subsets expressing the inhibitory CTLA-4 expression in were increased. Together, these results
could be indicative of a more tolerogenic phenotype in both cell subsets. However, the majority of the effects on T-cells were delayed and only observed at follow-up. In addition, surprisingly, a significant decrease in central memory and naïve Tregs was observed at follow-up and no significant changes in the frequency of circulating Tregs were found at 6 weeks [70]. In another clinical trial with 30 patients affected by T1D, 4g sodium butyrate or placebo were administered for 4 weeks [71]. The authors could not find any effect neither on peripheral immune cells or cytokine production, nor on CD4$^+$ or CD8$^+$ T cell subsets. However, they reported a reduction in autoreactive antigen-specific CD8$^+$ T cells, but since this could only be observed in a small subset with large individual variability, the authors concluded that oral butyrate may not have a beneficial effect on immune cells in T1D patients and is not in line with previous animal studies [71]. Another clinical trial using a dietary supplement in a cross-over design to assess change in gut microbiome, SCFA levels and glycemic control is currently underway [72] and will shed further light on the clinical implications. To summarize, while animal studies showed promising results for SCFA in T1D these could not or only partially be replicated in humans.

3.3. Rheumatoid Arthritis and Short Chain Fatty Acids

Rheumatoid arthritis (RA) is an autoimmune disease which affects the joints and leads to bone loss. T and B cells are thought to infiltrate the synovium and thus affect disease progression via release of pro-inflammatory mediators. Regarding T cell subtypes, especially CD4$^+$ Th1 and Th17 cells have been shown to be pathogenic [73], but there may also be a role of CD8$^+$ T cells [74]. A recent study assessing levels of SCFAs in blood and stool of patients has shown reduced levels of SCFAs in patients with RA compared to controls, although diverging effects were detected for serum and stool concentrations and per study [62,63]. Others have suggested that high levels of SCFAs may provide a protective effect in individuals at risk for RA development [61,75]. Animal studies have also suggested a beneficial role of higher SCFA concentrations: Takahashi et al. (2021), using a collagen-induced arthritis (CIA) and an SKG (i.e., T-cell mediated) mouse model for RA, showed that in vitro, butyrate increased follicular T regulatory cells, which reduce secretion of cytokines necessary for B cell activation and class switching. This in turn was linked to a more favorable disease outcome [76]. In line with this, Lucas et al. (2018) investigated the effect of SCFAs in two murine models of RA (CIA and K/BxN serum-induced model) and found improved bone homeostasis (i.e., decreased osteoclast differentiation and bone resorption), and beneficial effects on disease severity after an 8-week oral supplementation of acetate, propionate or butyrate [77]. The treatment enhanced serum levels of SCFAs and, as reported by others, the numbers of regulatory T cells were increased post-treatment. Interestingly, Lucas et al. (2018) also found that serum levels of TNF-α, IFN-γ and IL-10 were increased after butyrate treatment, but not after acetate or propionate treatment, suggesting differential systemic effects [77].

Yao et al. (2022) assessed levels of SCFAs in stool samples, B regulatory cells (Bregs) and Tregs (defined as CD4$^+$CD25$^+$) in 9 RA patients and 10 healthy volunteers [63]. Levels of acetate, propionate, butyrate and valerate were lower in patients compared to controls, and numbers of Tregs and Bregs were also reduced. However, SCFA levels correlated to Breg numbers, but not to Tregs. The authors went on to administer a treatment of SCFAs (either butyrate, acetate or propionate alone, or a combination) in a CIA RA mouse model before disease onset. They found that all SCFAs combined had the most beneficial effect on immune cell infiltration, joint swelling and arthritis scores and increased Breg frequency [63]. Congruent with the results observed in humans, SCFA levels correlated with Breg numbers in the periphery, but not with Treg numbers. In mice, IL-6, IL-18, TNF-α were downregulated, and IL-10 was upregulated in treated mice. Up until now, few human intervention studies have been conducted in RA. Häger et al. (2019) performed a dietary intervention in 36 patients with RA currently receiving treatment with disease-modifying anti-rheumatic drugs (DMARDs). They administered either high-fiber bars or cereals for 28 days [65]. After treatment, the authors observed higher numbers of peripheral Tregs,
and improved Th1/Th17 ratios in those with the high-fiber diet. These observations went alongside decreased IgA antibody levels, and improved quality of life. From the same study, Dürholz et al. (2020), report on a short term (30 day) intervention study with high dietary fiber intake in 29 patients with RA currently taking DMARDs and 10 healthy controls [64]. Levels of butyrate, propionate and acetate increased significantly in the serum of patients. Most cytokine levels remained unchanged, but chemokine-ligand 2, IL-18 and IL-33 decreased significantly [64]. In conclusion, first human trials have shown a beneficial effect of SCFAs in RA patients that were previously observed in animal models. Further studies are needed to corroborate these findings.

3.4. Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) comprises diseases causing inflammation in the gastrointestinal tract- including ulcerative colitis (UC) and Crohn’s disease (CD). Since aberrant immune cell function and infiltration has been shown for IBD [78], SCFAs may provide a targeted approach to regulate immune function, particularly given to proximity to their natural source. Overall patients with CD or active UC showed lower levels of propionate, acetate, butyrate and valerate, while those with UC in remission had levels comparable to controls, or even higher levels in the case of butyrate (for reviews see [58,79]). Given this apparent deficiency, it was early on assumed that SCFAs could have a beneficial effect in IBD. However, intervention studies up to date showed controversial effects. Several early studies have reported clinical improvement in patients with distal colitis treated with a 2-week [80] or 6-week [81] topical administration of SCFAs compared to placebo. In contrast, others did not observe any difference between placebo or verum condition in RCTs after a maximum of 6 weeks treatment with butyrate [82,83]. Indeed, a recent systematic review including 8 studies concluded that treatment with butyrate enemas did not improve disease outcome in UC, while no reliable data was available for CD [84]. We would like to direct readers to this current review for an overview on SCFA interventions in IBD.

When looking at the effects on immune cells, Berndt et al. (2012) even reported a worsening of induced colitis in a dextran sulfate sodium (DSS) mouse model after oral administration of butyrate [85]. Kespohl et al. (2017) investigated this question further and showed that the environment and dosage are crucial modulators of the SCFA induced effects [51]. Under steady state conditions, lower concentrations (100 or 200 mM) of butyrate administered as a 3-week oral treatment in mice did increase differentiation of Treg cells in the lamina propria. However, Treg numbers in the spleen or mesenteric lymph nodes were unchanged, and Th1 or Th17 numbers unaffected. Interestingly, when colitis was induced, orally administered butyrate at 100mM did not increase Treg numbers, but increased expression of T-bet and IFN-γ [51]. In line with this, Trapecar et al. (2020) noted that the environment and disease pathology are essential for these effects using a multi-organ model of UC [86]. In their experiments SCFAs did reduce innate immune activation in tissues; yet, depending on the condition, also increased effector activity of CD4+ T cells, which in turn aggravated inflammation [86]. In a recent trial with oral SCFA administration, Lee et al. (2022) showed an increase in both Treg and Th17 cells in the colon of mice subjected to a DSS-induced model of IBD after a 14-day oral administration of butyrate or a mix of butyrate, acetate and propionate, but did not observe attenuation of inflammation [87].

Opposing to the above-mentioned findings, Park et al. (2015) noted that although numbers of effector T cells were increased after SCFA treatment, the cells were less pathogenic and induced milder forms of colitis. Importantly, in the absence of an active immune response, no change of Th1 or Th17 cells was observed after acetate administration in the drinking water, but IL-10+ cells were increased in the cecum. However, during an induced infection, significantly enhanced frequencies of IL-17+ and IFN-γ+ cells were observed in cecum and spleen [7]. In line with this, Sun and colleagues found SCFAs to induce IL-10 production by Th1 cells, which limited the pathological effect of induced colitis. Additionally, in vitro experiments with cells of patients with IBD showed an induction of IL-10 and decrease of IL-17 production after culture with butyrate [88]. These findings suggest that
attention should be paid to the differential effects of SCFA concentration, as well as the milieu: during inflammatory conditions SCFAs may not necessarily have a dampening effect. It should also be noted that some studies have observed unwanted T cell mediated renal inflammation after oral administration of SCFAs at a concentration exceeding physiological levels, thus warranting caution with oral administration [89]. However, Marzocco et al. (2018) conducted an open label, dietary intervention study in patients with end stage renal disease receiving hemodialysis and showed improved signs of inflammation. After 12 weeks, a significant decrease in CRP, IL-2, IL-17 was observed, while IL-10 was significantly increased. No change was observed for IL-6, IFN-γ and TNF-α [90].

A recent article investigated the effect of SCFAs on γδ T cells in IBD [36]. This T cell type has been shown to be enhanced in the peripheral blood of post-infection IBD [91] and it was shown that their inflammatory activity as measured by IL-17 and IL-22 production, can be modified by the gut microbiota [36]. They also found a discrepancy in distribution of IL-17 producing γδ T cells in the small intestine or caecum/colon of mice, which linked to the production of short SCFAs. SCFAs, in particular propionate, inhibited IL-17 production by γδ T cells, while not affecting αβ T cells (IL-17 production in the overall tissue was actually increased) ex vivo [36]. However, in vivo this effect was only found in mice with an antibiotic-induced disruption of the microbiome, but not control mice: A 3-week oral intervention with propionate did not change γδ T cells in the control population, but reduced IL-17 production by γδ T cells in the antibiotic-treated group. Interestingly, the authors also replicated this effect in human material of IBD patients [36]. Lastly, Magnusson et al. (2020) recently showed that butyrate inhibited the activation and the proliferation of both circulating and intestinal human T cells in healthy controls as assessed in biopsies [92]. However, they also showed that butyrate did not downregulate cytokine secretion in inflamed tissues of patients, indicating that context and disease-dependent effects may occur [92]. To summarize, evidence for oral SCFA interventions in IBD is controversial. Data from mouse models generally suggest a dampening effect on inflammation, depending on dose and milieu, but human data in controlled trials is still sparse. These findings highlight the importance of assessing dose- and context specific factors. Disease state, concomitant medication, inflammatory status and nutrition should be taken into account in future studies. Table 4 provides an overview of all intervention studies.

Table 4. Interventions with short chain fatty acids in human patients with autoimmune disease assessing changes in T cells.

| Reference | Disease | n Cases/Controls | Intervention (RCT/Animal/IV) | Interventions+Dose | Duration | Cell Type Studied | Measured SCFA Concentration | Outcome |
|-----------|---------|-----------------|-----------------------------|--------------------|----------|------------------|-----------------------------|---------|
| [37]      | MS      | 91 MS, 24 HC    | Short-term propionate       | 1 g oral propionate daily | 14 days  | Treg, Th17       | ↑ Th17, ↑ Treg count, ↑ metabolism and function after 14 days and 90 days; ↑ Tregs suppressive capacity ex vivo; ↓ IL-10 ex vivo cell culture of propionate treated patients, mixed results for IL-17 |
|           |         |                 |                             |                    |          |                  |                             |         |
| MS        | 52 MS   | Long-term propionate | 1 g propionate daily/1-3 years | na                | na       | Improved clinical outcome (disability status and relapse rate) |
| RA        | 20 RA   | Short-term propionate | 1 g propionate daily | 14/28 days | Treg | na | ↑ Tregs after 14 days |
### Table 4. Cont.

| Reference | Disease | n Cases/Controls | Intervention (RCT/Animal/IV) | Intervention+Dose | Duration | Cell Type Studied |Measured SCFA Concentration Post Intervention| Outcome |
|-----------|---------|-----------------|-----------------------------|-------------------|----------|-------------------|-------------------------------------------|---------|
| [93]      | end stage renal disease | 10 ESRD patients/7HC | Open-label intervention study propionate | 2 × 500 mg daily sodium propionate | 30 days | Treg, CD25<sup>+</sup>CD127<sup>-</sup> na | ↑ Tregs over time, but not due to proliferation; ↓ after treatment with propionate; no consistent difference for granzyme, IFN-γ, IL-2, IL-17, and TNF-α producing CD4<sup>+</sup> and CD8<sup>+</sup>T-cells |
| [35], sample from [55] | MS | 34 non-obese MS (22 at fu); 6 obese MS (5 at fu) | propionate | 500 mg sodium-propionate (PA) capsules twice daily | 90 days | Treg, Th17 na | ↑ Tregs in non-obese group, non-significant ↑ in obese group; ↓ Th17 in obese group, non-significant ↓ in non-obese group |
| [70] | T1D | 20 T1D | HAMSAB dietary supplement | 40 g/day HAMSAB | 6 weeks | T cells, B cells, monocytes | plasma: ↑ acetate after 3 weeks, maximum at 6 weeks: 58% subjects acetate ↑ 2-fold; similar but less strong observations for propionate + butyrate; | ← CRP after butyrate treatment; ← monocyte subsets (compared to placebo) ← ex vivo cytokine production; ↓ plasma IL-8, MIP-1α, and bFGF at week 12 compared to baseline |
| [71] | T1D | 30 T1D | RCT with butyrate/placebo | 4 g sodium butyrate or placebo | 1 month | PBMCs (monocytes, autoreactive CD8<sup>+</sup> T cells) | ← fecal acetate, ↓ fecal propionate and butyrate | ↑ Tregs, ↑ Th1/Th17 ratio; ← CD4 and CD8 numbers. Improved physical & mental quality of life and disability scores, ↓ IgA; ← anti-citrullinated vimentin p18 peptide antibody levels; ← for IL-1β, IFN-α2, IFN-γ, TNF-α, IL-6, CXCL-8 (IL-8), IL-10, IL-12p70, IL-17A and IL-23; ↓ for CCL-2, IL-18 and IL-33 |
| [64,65] | RA | 36 RA | dietary intervention high fiber bars | high-fiber bars 15–30 g/day or cereals | 28 days (14 + 14)/30 days | Tregs, Th1, Th17 | ↑ acetate and butyrate and propionate after 30 days | Abbreviations: ↑ increase in; ← no change in; ↓ IgA: decrease in; CSF: cerebrospinal fluid; HAMS/A/B/P: high-amylose maize-resistant starch modified with acetate/butyrate or propionate, CTLA4: cytotoxic T-lymphocyte-associated Protein 4, MIP: Macrophage Inflammatory Proteins, and bFGF: basic fibroblast growth factor, RCT: randomized controlled trial; PBMC: peripheral blood mononuclear cells; CRP: C-reactive protein; CXCL: chemokine (C-X-C motif) ligand; CCL: chemokine ligand, na: not applicable. |

### 4. Conclusions

Some human bacterial commensal species and their metabolites have been described to promote anti-inflammatory effects and suppress the over activation of the immune system. SCFAs are the major and well-characterized class of commensal-derived metabolites, are capable of regulating metabolic and epigenetic processes in T lymphocytes and may thus maintain immune homeostasis and protect against immune-pathogenesis. In vitro studies
have shown that at the right dose, SCFAs initiate differentiation of Tregs, and concurrently suppress development of pathogenic Th17 cells. SCFA-dependent regulation of Treg and Th17 cell plasticity crucially contributes to immune homeostasis in the intestine. In this review we reported on recent intervention studies in animals and humans, suggesting that SCFA-based interventions in humans and mice have the potential to shape the immunological environment in various tissues and may protect from autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and diabetes. While the first few studies in humans do report favorable outcomes for RA and MS, this effect could not be observed for interventions in T1D, and SCFA can also induce inflammatory T cell subsets, depending on the local milieu. Most current evidence in humans comes from open label studies and concentrations of SCFAs observed in the periphery are likely below the threshold to replicate the potent effects observed in in vitro studies, albeit more moderate effects have been observed. The effect of SCFA interventions on clinical symptoms and peripheral circulating immune cells is still unclear and needs further investigation in randomized controlled trials. Furthermore, besides SCFAs, several other microbiota-derived molecules such as secondary bile acids, tryptophan catabolites and polyamines are potentially able to modulate the mucosal immune system. Similar to SCFAs, tryptophan metabolites generated by commensal bacteria appear to affect intestinal T cell differentiation and impact immune responses. Thus, next to the commensal microbiota themselves, specific, diffusible molecules such as SCFAs exhibiting a potent immuno-regulatory activity should be therapeutically exploited in the future clinical trials. The next step in establishing promising biotherapeutic agents derived from the human microbiome is to decipher more thoroughly complex interactions of microbiota-derived molecules with different immune cell subsets.

**Author Contributions:** C.S. and A.V.; writing—original draft preparation, C.S. and A.V.; writing—review and editing: all co-authors.; visualization: A.V.; supervision, A.V., A.W., A.R.; project administration, C.S.; funding acquisition, C.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by “Goethe University-Frankfurter Forschungsförderung Nachwuchswissenschaftler 2021”.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All Data is reported in the manuscript/no analysis was performed on original data.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Dopkins, N.; Nagarkatti, P.S.; Nagarkatti, M. The Role of Gut Microbiome and Associated Metabolome in the Regulation of Neuroinflammation in Multiple Sclerosis and Its Implications in Attenuating Chronic Inflammation in Other Inflammatory and Autoimmune Disorders. *Immunoology* 2018, 154, 178–185. [CrossRef] [PubMed]

2. Corrêa-Oliveira, R.; Fachi, J.L.; Vieira, A.; Sato, F.T.; Vinolo, M.A.R. Regulation of immune cell function by short-chain fatty acids. *Clin. Transl. Immunol.* 2016, 5, e73. [CrossRef]

3. Parada Venegas, D.; De la Fuente, M.K.; Landskron, G.; González, M.J.; Quera, R.; Dijkstra, G.; Harmsen, H.J.M.; Faber, K.N.; Hermoso, M.A. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. *Front. Immunol.* 2019, 10, 277. [CrossRef] [PubMed]

4. Kim, M.; Qie, Y.; Park, J.; Kim, C.H. Gut Microbial Metabolites Fuel Host Antibody Responses. *Cell Host Microbe* 2016, 20, 202–214. [CrossRef] [PubMed]

5. Takeuchi, T.; Miyauuchi, E.; Kanaya, T.; Kato, T.; Nakanishi, Y.; Watanabe, T.; Kitami, T.; Taida, T.; Sasaki, T.; Negishi, H. Acetate Differentially Regulates IgA Reactivity to Commensal Bacteria. *Nature* 2021, 595, 560–564. [CrossRef]

6. Smith, P.M.; Howitt, M.R.; Panikov, N.; Michaud, M.; Gallini, C.A.; Bohllooly-Y, M.; Glickman, J.N.; Garrett, W.S. The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T Reg Cell Homeostasis. *Science* 2013, 341, 569–573. [CrossRef]

7. Park, J.; Kim, M.; Kang, S.G.; Jannasch, A.H.; Cooper, B.; Patterson, J.; Kim, C.H. Short-Chain Fatty Acids Induce Both Effector and Regulatory T Cells by Suppression of Histone Deacetylases and Regulation of the MTOR–S6K Pathway. *Mucosal Immunol.* 2015, 8, 80–93. [CrossRef] [PubMed]
Cummings, J.; Pomare, E.W.; Branch, W.J.; Naylor, C.P.; MacFarlane, G. Short Chain Fatty Acids in Human Large Intestine, Portal, Hepatic and Venous Blood. *Gut* 1987, **28**, 1221–1227. [CrossRef]

Blak, E.E.; Canfora, E.E.; Theis, S.; Frost, G.; Groen, A.K.; Mitthieux, G.; Nauta, A.; Scott, K.; Stahl, B.; Van Harsselaar, J. Short Chain Fatty Acids in Human Gut and Metabolic Health. *Benef. Microbes* 2020, **11**, 411–455. [CrossRef]

Rios-Covián, D.; Ruas-Madiedo, P.; Margolles, A.; Gueimonde, M.; De Los Reyes-gavilán, C.G.; Salazar, N. Intestinal Short Chain Fatty Acids and Their Link with Diet and Human Health. *Front. Microbiol.* 2016, **7**, 185. [CrossRef] [PubMed]

Deleu, S.; Machiels, K.; Raes, J.; Verbeke, K.; Vermeire, S. Short Chain Fatty Acids and Its Producing Organisms: An Overlooked Therapy for IBD? *eBioMedicine* 2021, **66**, 103293. [CrossRef] [PubMed]

Riviere, A.; Selak, M.; Lantin, D.; Leroy, F.; De Vuyst, L. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. *Front. Microbiol.* 2016, **7**, 979. [CrossRef] [PubMed]

Donohoe, D.R.; Garge, N.; Zhang, X.; Sun, W.; O’Connell, T.M.; Bunger, M.K.; Bultman, S.J. The Microbiome and Butyrate Regulate Energy Metabolism and Autophagy in the Mammalian Colon. *Cell Metab.* 2013, **11**, 517–526. [CrossRef]

Iraporda, C.; Errea, A.; Romanin, D.E.; Cayet, D.; Pereyra, E.; Pignataro, O.; Sirard, J.C.; Garrote, G.L.; Abraham, A.G.; Rumbo, M. Lactate and Short Chain Fatty Acids Produced by Microbial Fermentation Downregulate Proinflammatory Responses in Intestinal Epithelial Cells and Myeloid Cells. *Immunobiology* 2015, **220**, 1161–1169. [CrossRef] [PubMed]

Macia, L.; Tan, J.; Vieira, A.T.; Leach, K.; Stanley, D.; Luong, S.; Maruya, M.; McKenzie, C.I.; Hijikata, A.; Wong, C. Metabolite-Sensing Receptors GPR43 and GPR109A Facilitate Dietary Fibre-Induced Gut Homeostasis through Regulation of the Inflammation and Energy Metabolism Axis. *Nat. Commun.* 2015, **6**, 6734. [CrossRef]

Sakata, T. Pitfalls in Short-Chain Fatty Acid Research: A Methodological Review. *Anim. Sci. J.* 2019, **90**, 3–13. [CrossRef] [PubMed]

Obson, A.; Gustavsen, S.; Nguyen, T.D.; Nyman, M.; Langkilde, A.R.; Hansen, T.H.; Sellebjerg, F.; Oturai, A.B.; Bach Søndergaard, H. Serum Short-Chain Fatty Acids and Associations With Inflammation in Newly Diagnosed Patients With Multiple Sclerosis and Healthy Controls. *Front. Immunol.* 2021, **12**, 661493. [CrossRef] [PubMed]

Jakobsdottir, G.; Bjørgv Wheels, J.H.; Skovbjerg, H.; Nyman, M. Fasting Serum Concentration of Short-Chain Fatty Acids in Subjects with Microscopic Colitis and Celiac Disease: No Difference Compared with Controls, but between Genders. *Scand. J. Gastroenterol.* 2013, **48**, 696–701. [CrossRef]

Pomare, E.W.; Branch, W.J.; Cummings, J.H. Carbohydrate Fermentation in the Human Colon and Its Relation to Acetate Concentrations in Venous Blood. *J. Clin. Investig.* 1985, **75**, 1448–1454. [CrossRef]

Holling, T.M.; Schooten, E.; van Den Elsen, P.J. Function and Regulation of MHC Class II Molecules in T-Lymphocytes: Of Mice and Men. *Hum. Immunol.* 2004, **65**, 282–290. [CrossRef]

Arpaia, N.; Campbell, C.; Fan, X.; Dikiy, S.; van der Veeken, J.; deRoos, P.; Liu, H.; Cross, J.R.; Pfeffer, K.; Coffer, P.J.; et al. Metabolites Produced by Commensal Bacteria Promote Peripheral Regulatory T-Cell Generation. *Nature* 2013, **504**, 451–455. [CrossRef] [PubMed]

Furusawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakao, G.; Takahashi, D.; Nakanishi, Y.; Uetake, C.; Kato, K.; Kato, T.; et al. Commensal Microbe-Derived Butyrate Induces the Differentiation of Colonic Regulatory T Cells. *Nature* 2013, **504**, 446–450. [CrossRef] [PubMed]

Park, S.-G.; Mathur, R.; Long, M.; Hosh, N.; Hao, L.; Hayden, M.S.; Ghosh, S. T Regulatory Cells Maintain Intestinal Homeostasis by Suppressing GÎ” T Cells. *Immunity* 2010, **31**, 79–803. [CrossRef] [PubMed]

Cosovanu, C.; Neumann, C. The Many Functions of Foxp3+ Regulatory T Cells in the Intestine. *Front. Immunol.* 2020, **11**, 600973. [CrossRef] [PubMed]

O’Connor, W.; Zenewicz, I.A.; Flavell, R.A. The Dual Nature of TH 17 Cells: Shifting the Focus to Function. *Nat. Immunol.* 2010, **11**, 471–476. [CrossRef] [PubMed]

Bank, I. The Role of Gamma Delta T Cells in Autoimmune Rheumatic Diseases. *Cells* 2020, **9**, 462. [CrossRef]

Vantourout, P.; Hayday, A. Six-of-the-Best: Unique Contributions of Î” T Cells to Immunology. *Nat. Rev. Immunol.* 2013, **13**, 88–110. [CrossRef]

Carding, S.R.; Egan, P.J. Î” T Cells: Functional Plasticity and Heterogeneity. *Nat. Rev. Immunol.* 2002, **2**, 336–345. [CrossRef]

Littman, D.R.; Rudensky, A.Y. Th17 and Regulatory T Cells in Mediating and Restraining Inflammation. *Cell* 2010, **140**, 845–858. [CrossRef]

Atarashi, K.; Tanoue, T.; Ando, M.; Kamada, N.; Nagano, Y.; Narushima, S.; Suda, W.; Imaoka, A.; Setoyama, H.; Nagamori, T.; et al. Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells. *Cell* 2015, **163**, 367–380. [CrossRef]

Ivanov, II.; Atarashi, K.; Manel, N.; Brodie, E.L.; Shima, T.; Karaoz, U.; Wei, D.; Goldfarb, K.C.; Santee, C.A.; Lynch, S.V.; et al. Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria. *Cell* 2009, **138**, 485–498. [CrossRef]

Chung, H.; Pamp, S.J.; Hill, J.A.; Surana, N.K.; Edelman, S.M.; Troy, E.B.; Reading, N.C.; Villablanca, E.J.; Wang, S.; Mora, J.R.; et al. Gut Immune Maturation Depends on Colonization with a Host-Specific Microbiota. *Cell* 2012, **149**, 1578–1593. [CrossRef] [PubMed]

Muranaki, P.; Restifo, N.P. Essentials of Th17 Cell Commitment and Plasticity. *Blood* 2013, **121**, 2402–2414. [CrossRef] [PubMed]

Wu, W.; Chen, F.; Liu, Z.; Cong, Y. Microbiota-Specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease. *Inflamm. Bowel Dis.* 2016, **22**, 1473–1482. [CrossRef] [PubMed]

Chen, L.; Sun, M.; Wu, W.; Chen, F.; Huang, X.; Xiao, Y.; Yao, S.; Cong, Y. Short Chain Fatty Acids Differentially Regulate Differentiation and Function of Th1 and Th17 Cells in the Intestines. *J. Immunol.* 2017, **198**, 16. [CrossRef]
36. Dupraz, L.; Magniez, A.; Rohlion, N.; Richard, M.L.; Da Costa, G.; Touch, S.; Mayeur, C.; Planchais, J.; Agus, A.; Danne, C. Gut Microbiota-Derived Short-Chain Fatty Acids Regulate IL-17 Production by Mouse and Human Intestinal Γδ T Cells. Cell Rep. 2021, 36, 109332. [CrossRef]

37. Duscha, A.; Gisevius, B.; Hirschberg, S.; Yissachar, N.; Stangl, G.I.; Eilers, E.; Bader, V.; Haase, S.; Kaisler, J.; David, C. Propionionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism. Cell 2020, 180, 1067–1080. [CrossRef]

38. Trompette, A.; Gollwitzer, E.S.; Pattaroni, C.; Lopez-Mejia, I.C.; Riva, E.; Ferneton, J.; Ubags, N.; Fajas, L.; Nicod, L.P.; Marsland, B.J. Dietary Fiber Confers Protection against Flu by Shaping Ly6c− Patrolling Monocyte Hematopoiesis and CD8+ T Cell Metabolism. Immunology 2018, 48, 992–1005. [CrossRef]

39. Bachem, A.; Makhlouf, C.; Binger, K.J.; de Souza, D.P.; Tull, D.; Hochheiser, K.; Whitney, P.G.; Fernandez-Ruiz, D.; Dähling, S.; Kastenmüller, W. Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8+ T Cells. Immunology 2019, 51, 285–297. [CrossRef]

40. Donohoe, D.R.; Holley, D.; Collins, L.B.; Montgomery, S.A.; Whitmore, A.C.; Hillhouse, A.; Curry, K.P.; Renner, S.W.; Greenwalt, A.; Ryan, E.P. A Gnotobiotic Mouse Model Demonstrates That Dietary Fiber Protects against Colorectal Tumorigenesis in a Microbiota-and Butyrate-Dependent Manner. Cancer Discov. 2014, 4, 1387–1397. [CrossRef]

41. Williams, E.A.; Coxhead, J.M.; Mathers, J.C. Anti-Cancer Effects of Butyrate: Use of Micro-Arrangement to Investigate Mechanisms. Proc. Nutr. Soc. 2003, 62, 107–115. [CrossRef] [PubMed]

42. Qiu, J.; Villa, M.; Sanin, D.E.; Buck, M.D.; O’Sullivan, D.; Ching, K.; Matsushita, M.; Grzes, K.M.; Winkler, F.; Chang, C.-H. Acetate Promotes T Cell Effector Function during Glucose Restriction. Cell Rep. 2019, 27, 2063–2074. [CrossRef]

43. He, Y.; Fu, L.; Li, Y.; Wang, W.; Gong, M.; Zhang, J.; Dong, X.; Huang, J.; Wang, Q.; Mackay, C.R. Gut Microbial Metabolites Facilitate Anticancer Therapy Efficacy by Modulating Cytotoxic CD8+ T Cell Immunity. Cell Metab. 2021, 33, 988–1000. [CrossRef]

44. Luu, M.; Riester, Z.; Baldrich, A.; Reichardt, N.; Yuille, S.; Busetti, A.; Klein, M.; Wempe, A.; Leister, H.; Raifer, H. Microbial Short-Chain Fatty Acids Modulate CD8+ T Cell Responses and Improve Adoptive Immunotherapy for Cancer. Nat. Commun. 2021, 12, 4077. [CrossRef]

45. Park, E.M.; Chelwanambi, M.; Bhutiani, N.; Kroemer, G.; Zitvogel, L.; Wargo, J.A. Targeting the Gut and Tumor Microbiota in Cancer. Nat. Med. 2022, 28, 690–703. [CrossRef]

46. Qi Hui, S.; Hua, L.; Wen Shan, Y.; Zhaohong, T.; Sharada, R.; Matthew Wook, C.; Louis Yi Ann, C. The Divergent Immunomodulatory Effects of Short-Chain Fatty Acids and Medium Chain Fatty Acids. Int. J. Mol. Sci. 2021, 22, 6453. [CrossRef]

47. COUTZAC, J.; JOUNIAUX, J.-M.; PACI, A.; SCHMIDT, J.; MAULLARDO, D.; SECK, A.; AVSATOURIAN, V.; CASSARD, L.; SAULNIER, P.; LACROIX, L.; et al. Systemic Short Chain Fatty Acids Limit Antitumor Effect of CTLA-4 Blockade in Hosts with Cancer. Nat. Commun. 2020, 11, 2168. [CrossRef]

48. Cavaglieri, C.R.; Nishiyama, A.; Fernandes, L.C.; Curi, R.; Miles, E.A.; Calder, P.C. Differential Effects of Short-Chain Fatty Acids on Proliferation and Production of pro- and Anti-Inflammatory Cytokines by Cultured Lymphocytes. Life Sci. 2003, 73, 1683–1690. [CrossRef]

49. Magnusson, M.K.; Vidal, A.; Maasfgh, L.; Isaksson, S.; Malhotra, R.; Olsson, H.K.; Öhman, L. Impaired Butyrate Induced Regulation of T Cell Surface Expression of CTLA-4 in Patients with Ulcerative Colitis. Int. J. Mol. Sci. 2021, 22, 3084. [CrossRef]

50. Haghikia, A.; Jörg, S.; Duscha, A.; Berg, J.; Manzel, A.; Waschbisch, A.; Hammer, A.; Lee, D.-H.; May, C.; Wilck, N. Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine. Immunology 2015, 43, 817–829. [CrossRef]

51. Kesphohl, M.; Vachharajani, N.; Luu, M.; Harb, H.; Pautz, S.; Wolf, S.; Stillner, N.; Walker, A.; Schmitt-Kopplin, P.; Boettger, T.; et al. The Microbial Metabolite Butyrate Induces Expression of Th1-Associated Factors in CD4+ T Cells. Front. Immunol. 2017, 8, 1036. [CrossRef]

52. Dalile, B.; Vervliet, B.; Bergonzelli, G.; Verbeke, K.; Van Oudenhove, L. Colon-Delivered Short-Chain Fatty Acids Attenuate the Cortisol Response to Psychosocial Stress in Healthy Men: A Randomized, Placebo-Controlled Trial. Neuropeptides 2020, 65, 2257–2266. [CrossRef] [PubMed]

53. Hemmer, B.; Kerschensteiner, M.; Korn, T. Role of the Innate and Adaptive Immune Responses in the Course of Multiple Sclerosis. Lancet Neurol. 2015, 14, 406–419. [CrossRef]

54. Park, J.; Wang, Q.; Wu, Q.; Mao-Draayer, Y.; Kim, C.H. Bidirectional Regulatory Potentials of Short-Chain Fatty Acids and Their G-Protein-Coupled Receptors in Autoimmune Neuroinflammation. Sci. Rep. 2019, 9, 8837. [CrossRef] [PubMed]

55. Trend, S.; Jeffler, J.; Jones, A.P.; Cha, L.; Gorman, S.; Brown, D.A.; Breit, S.N.; Kermode, A.G.; French, M.A.; Ward, N.C.; et al. Associations of Serum Short-Chain Fatty Acids with Circulating Immune Cells and Serum Biomarkers in Patients with Multiple Sclerosis. Sci. Rep. 2021, 11, 5244. [CrossRef] [PubMed]

56. Becker, A.; Abuabzab, M.; Schwierz, A.; Walter, S.; Faßbender, K.C.; Fousse, M.; Unger, M.M. Short-Chain Fatty Acids and Intestinal Inflammation in Multiple Sclerosis: Modulation of Female Susceptibility by Microbial Products? Autoimmun. Highlights 2021, 12, 7. [CrossRef]

57. Perez-Perez, P.; Dominguez-Mozo, M.I.; Alonso-Gomez, A.; Medina, S.; Villarrubia, N.; Fernandez-Velasco, J.I.; Garcia-Martinez, M.A.; Garcia-Calvo, E.; Estévez, H.; Costa-Frossard, L.; et al. Acetate Correlates with Disability and Immune Response in Multiple Sclerosis. PeerJ 2020, 8, e10220. [CrossRef]

58. Zeng, Q.; Gong, J.; Liu, X.; Chen, C.; Sun, X.; Li, H.; Zhou, Y.; Cui, C.; Wang, Y.; Yang, Y.; et al. Gut Dysbiosis and Lack of Short Chain Fatty Acids in a Chinese Cohort of Patients with Multiple Sclerosis. Neurochem. Int. 2019, 129, 104468. [CrossRef]
59. Huang, J.; Pearson, J.A.; Peng, J.; Hu, Y.; Sha, S.; Xing, Y.; Huang, G.; Li, X.; Hu, F.; Xie, Z.; et al. Gut Microbial Metabolites Alter IgA Immunity in Type 1 Diabetes. JCI Insight 2020, 5, e135718. [CrossRef]

60. Winther, S.A.; Mannerla, M.M.; Frimodt-Moller, M.; Persson, F.; Hansen, T.W.; Lehto, M.; Hörkkö, S.; Blaut, M.; Forsblom, C.; Groop, L.-H.; et al. Faecal Biomarkers in Type 1 Diabetes with and without Diabetic Nephropathy. Sci. Rep. 2021, 11, 15208. [CrossRef]

61. Martinsson, K.; Dürholz, K.; Schett, G.; Zaiss, M.M.; Castbom, A. Higher Serum Levels of Short-Chain Fatty Acids Are Associated with Non-Progression to Arthritis in Individuals at Increased Risk of RA. Ann. Rheum. Dis. 2022, 81, 445–447. [CrossRef]

62. Rossier, E.C.; Piper, C.J.M.; Matei, D.E.; Blair, P.A.; Rendeiro, A.F.; Orford, M.; Alber, D.G.; Krausgruber, T.; Catalan, D.; Klein, N. Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-Hydrocarbon Receptor Activation in Regulatory B Cells. Cell Metab. 2020, 31, 837–851. [CrossRef]

63. Yao, Y.; Cai, X.; Zheng, Y.; Zhang, M.; Fei, W.; Sun, D.; Zhao, M.; Ye, Y.; Zheng, C. Short-chain Fatty Acids Regulate B Cells Differentiation via FFAR2 to Alleviate Rheumatoid Arthritis. Br. J. Pharmacol. 2022, 1–15. [CrossRef]

64. Dürholz, K.; Hofmann, J.; Iljazovic, A.; Häger, J.; Lucas, S.; Sarter, K.; Strowig, T.; Bang, H.; Rech, J.; Schett, G. Dietary Short-Term Fiber Interventions in Arthritis Patients Increase Systemic SCFA Levels and Regulate Inflammation. Nutrients 2020, 12, 3207. [CrossRef]

65. Häger, J.; Bang, H.; Hagen, M.; Frech, M.; Traeger, P.; Sokolova, M.V.; Steffen, U.; Tascilar, K.; Sarter, K.; Schett, G. The Role of Dietary Fiber in Rheumatoid Arthritis Patients: A Feasibility Study. Nutrients 2019, 11, 2392. [CrossRef] [PubMed]

66. Haase, S.; Mäurer, J.; Duscha, A.; Lee, D.-H.; Balogh, A.; Gold, R.; Müller, D.N.; Haghiakia, A.; Linker, R.A. Propionic Acid Rescues High-Fat Diet Enhanced Immunopathology in Autoimmunity via Effects on Th17 Responses. Front. Immunol. 2021, 12, 701626. [CrossRef]

67. Galicia-Garcia, U.; Benito-Vicente, A.; Jebari, S.; Larrea-Sebal, A.; Siddiqi, H.; Uribe, K.B.; Ostolaza, H.; Martin, C. Pathophysiology of Type 2 Diabetes Mellitus. Int. J. Mol. Sci. 2020, 21, 6275. [CrossRef] [PubMed]

68. Burrack, A.L.; Martinov, T.; Fife, B.T. T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes. Front. Endocrinol. 2017, 8, 343. [CrossRef] [PubMed]

69. Maríñño, E.; Richards, J.L.; McLeod, K.H.; Stanley, D.; Yap, Y.A.; Knight, J.; McKenzie, C.; Kranich, J.; Oliveira, A.C.; Rossello, F.J. Gut Microbial Metabolites Limit the Frequency of Autoimmune T Cells and Protect against Type 1 Diabetes. Nat. Immunol. 2017, 18, 552–562. [CrossRef] [PubMed]

70. Bell, K.J.; Saad, S.; Tillett, B.J.; McGuire, H.M.; Bordbar, S.; Yap, Y.A.; Nguyen, L.T.; Wilkins, M.R.; Corley, S.; Brodie, S. SCFA Supplementation Is Associated with Microbiota and Immune Modulation in Diabetes. Res. Sq. 2022, 10, 9. [CrossRef]

71. de Groot, P.F.; Nikolic, T.; Imangaliyev, S.; Bekkering, S.; Duinkerken, G.; Keij, F.M.; Herrema, H.; Winkelmeijer, M.; Kroon, J.; Levin, E. Oral Butyrate Does Not Affect Innate Immunity and Islet Autoimmunity in Individuals with Longstanding Type 1 Diabetes: A Randomised Controlled Trial. Diabetologia 2020, 63, 597–610. [CrossRef]

72. Ismail, H.M.; Evans-Molina, C.; DiMeglio, L.A. 57437 Effects of Prebiotics on the Gut Microbiome Profile, Beta-Cell Function and Immune Markers in Newly-Diagnosed Type 1 Diabetes. J. Clin. Transl. Sci. 2021, 5, 38. [CrossRef]

73. Kamali, A.N.; Noorabakhsh, S.M.; Hamedifar, H.; Jadidi-Niaragh, F.; Yazdani, R.; Bautista, J.M.; Azizi, G. A Role for Th1-like Th17 Cells in the Pathophysiology of Inflammatory and Autoimmune Disorders. Mol. Immunol. 2019, 105, 107–115. [CrossRef]

74. Petrelli, A.; van Wijk, F. CD8+ T Cells in Human Autoimmune Arthritis: The Unusual Suspects. Nat. Rev. Rheumatol. 2016, 12, 421–428. [CrossRef] [PubMed]

75. Weavers, H.; Martin, P. The Cell Biology of Inflammation: From Common Traits to Remarkable Immunological Adaptations. J. Cell Biol. 2020, 219. [CrossRef]

76. Takahashi, D.; Hoshina, N.; Kabumoto, Y.; Maeda, Y.; Suzuki, A.; Tanabe, H.; Isobe, J.; Yamada, T.; Muroi, K.; Yanagisawa, Y. Microbiota-Derived Butyrate Limits the Autoimmune Response by Promoting the Differentiation of Follicular Regulatory T Cells. EBioMedicine 2020, 58, 102913. [CrossRef] [PubMed]

77. Lucas, S.; Omata, Y.; Hofmann, J.; Böttcher, M.; Iljazovic, A.; Sarter, K.; Albrecht, O.; Schulz, O.; Krishnacoumar, B.; Krönke, G. Short-Chain Fatty Acids Regulate Systemic Bone Mass and Protect from Pathological Bone Loss. Nat. Commun. 2018, 9, 55. [CrossRef]

78. Wallace, K.L.; Zheng, L.-B.; Kanazawa, Y.; Shih, D.Q. Immunopathology of Inflammatory Bowel Disease. World J. Gastroenterol. 2014, 20, 6. [CrossRef]

79. Xu, H.-M.; Zhao, H.-L.; Guo, G.-J.; Xu, J.; Zhou, Y.-L.; Huang, H.-L.; Nie, Y.-Q. Characterization of Short-Chain Fatty Acids in Patients with Ulcerative Colitis: A Meta-Analysis. BMC Gastroenterol. 2022, 22, 117. [CrossRef] [PubMed]

80. Scheppach, W. Treatment of Distal Ulcerative Colitis with Short-Chain Fatty Acid Enemas a Placebo-Controlled Trial. Dig. Dis. Sci. 1996, 41, 225!–2259. [CrossRef]

81. Vernia, P.; Cittadini, M.; Caprilli, R.; Torsoli, A. Topical Treatment of Refractory Distal Ulcerative Colitis with 5-ASA and Sodium Butyrate. Dig. Dis. Sci. 1995, 40, 305–307. [CrossRef]

82. Steinhardt, A.H.; Hiruki, T.; Brzezinski, A.; Baker, J.P. Treatment of Left-Sided Ulcerative Colitis with Butyrate Enemas: A Controlled Trial. Aliment. Pharmacol. Ther. 1996, 10, 729–736. [CrossRef] [PubMed]

83. Breuer, R.I.; Soergel, K.H.; Lashner, B.A.; Christ, M.L.; Hanauer, S.B.; Vanagunas, A.; Harig, J.M.; Keshavarzian, A.; Robinson, M.; Sellin, J.H.; et al. Short Chain Fatty Acid Rectal Irrigation for Left-Sided Ulcerative Colitis: A Randomised, Placebo Controlled Trial. Gut 1997, 40, 485–491. [CrossRef] [PubMed]
84. Jamka, M.; Kokot, M.; Kaczmarek, N.; Bermagambetova, S.; Nowak, J.K.; Walkowiak, J. The Effect of Sodium Butyrate Enemas Compared with Placebo on Disease Activity, Endoscopic Scores, and Histological and Inflammatory Parameters in Inflammatory Bowel Diseases: A Systematic Review of Randomised Controlled Trials. *Complement. Med. Res.* 2021, 28, 344–356. [CrossRef]

85. Berndt, B.E.; Zhang, M.; Owyang, S.Y.; Cole, T.S.; Wang, T.W.; Luther, J.; Veniaminova, N.A.; Merchant, J.L.; Chen, C.-C.; Huffnagle, G.B. Butyrate Increases IL-23 Production by Stimulated Dendritic Cells. *Am. J. Physiol. Liver Physiol.* 2012, 303, G1384–G1392. [CrossRef]

86. Trapecar, M.; Communal, C.; Velazquez, J.; Maass, C.A.; Huang, Y.-J.; Schneider, K.; Wright, C.W.; Butty, V.; Eng, G.; Yilmaz, O.; et al. Gut-Liver Physiomimetics Reveal Paradoxical Modulation of IBD-Related Inflammation by Short-Chain Fatty Acids. *Cell Syst.* 2020, 10, 223–239. [CrossRef]

87. Lee, J.G.; Lee, J.; Lee, A.; Jo, S.V.; Park, C.H.; Han, D.S.; Eun, C.S. Impact of Short-Chain Fatty Acid Supplementation on Gut Inflammation and Microbiota Composition in a Murine Colitis Model. *J. Nutr. Biochem.* 2022, 101, 108926. [CrossRef]

88. Sun, M.; Wu, W.; Chen, L.; Yang, W.; Huang, X.; Ma, C. Microbiota-Derived Short-Chain Fatty Acids Promote TH1 Cell IL-10 Production to Maintain Intestinal Homeostasis. *Nat Commun.* 2018, 9, 3555. [CrossRef]

89. Park, J.; Goergen, C.J.; HogenEsch, H.; Kim, C.H. Chronically Elevated Levels of Short-Chain Fatty Acids Induce T Cell–Mediated Ureteritis and Hydronephrosis. *J. Immunol.* 2016, 196, 2388–2400. [CrossRef] [PubMed]

90. Marzocco, S.; Fazeli, G.; Di Micco, L.; Autore, G.; Adesso, S.; Dal Piaz, F.; Heidland, A.; Di Iorio, B. Supplementation of Short-Chain Fatty Acid, Sodium Propionate, in Patients on Maintenance Hemodialysis: Beneficial Effects on Inflammatory Parameters and Gut-Derived Uremic Toxins, a Pilot Study (PLAN Study). *J. Clin. Med.* 2018, 7, 315. [CrossRef] [PubMed]

91. Dong, L.W.; Sun, X.N.; Ma, Z.C.; Fu, J.; Liu, F.J.; Huang, B.L.; Liang, D.C.; Sun, D.M.; Lan, C. Increased Vδ1γδ T Cells Predominantly Contributed to IL-17 Production in the Development of Adult Human Post-Infectious Irritable Bowel Syndrome. *BMC Gastroenterol.* 2021, 21, 271. [CrossRef] [PubMed]

92. Magnusson, M.K.; Isaksson, S.; Öhman, L. The Anti-Inflammatory Immune Regulation Induced by Butyrate Is Impaired in Inflamed Intestinal Mucosa from Patients with Ulcerative Colitis. *Inflammation* 2020, 43, 507–517. [CrossRef]

93. Meyer, F.; Seibert, F.S.; Nienen, M.; Welzel, M.; Beisser, D.; Bauer, F.; Rohn, B.; Westhoff, T.H.; Stervbo, U.; Babel, N. Propionate Supplementation Promotes the Expansion of Peripheral Regulatory T-Cells in Patients with End-Stage Renal Disease. *J. Nephrol.* 2020, 33, 817–827. [CrossRef] [PubMed]